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Although the number of papers about ‘‘vanadium’’ has doubled in the last decade, the studies
about ‘‘vanadium and actin’’ are scarce. In the present review, the effects of vanadyl, vanadate
and decavanadate on actin structure and function are compared. Decavanadate 51V NMR signals,
at 516 ppm, broadened and decreased in intensity upon actin titration, whereas no effects were
observed for vanadate monomers, at 560 ppm. Decavanadate is the only species inducing actin
cysteine oxidation and vanadyl formation, both processes being prevented by the natural ligand
of the protein, ATP. Vanadyl titration with monomeric actin (G-actin), analysed by EPR
spectroscopy, reveals a 1 : 1 binding stoichiometry and a Kd of 7.5 mM
1. Both decavanadate and
vanadyl inhibited G-actin polymerization into actin filaments (F-actin), with a IC50 of 68 and
300 mM, respectively, as analysed by light scattering assays, whereas no effects were detected for
vanadate up to 2 mM. However, only vanadyl (up to 200 mM) induces 100% of G-actin intrinsic
fluorescence quenching, whereas decavanadate shows an opposite effect, which suggests the
presence of vanadyl high affinity actin binding sites. Decavanadate increases (2.6-fold) the actin
hydrophobic surface, evaluated using the ANSA probe, whereas vanadyl decreases it (15%). Both
vanadium species increased the e-ATP exchange rate (k = 6.5  103 s1 and 4.47  103 s1 for
decavanadate and vanadyl, respectively). Finally, 1H NMR spectra of G-actin treated with
0.1 mM decavanadate clearly indicate that major alterations occur in protein structure, which are
much less visible in the presence of ATP, confirming the preventive effect of the nucleotide on the
decavanadate interaction with the protein. Putting it all together, it is suggested that actin, which
is involved in many cellular processes, might be a potential target not only for decavanadate but
above all for vanadyl. By affecting actin structure and function, vanadium can regulate many
cellular processes of great physiological significance.
1. Introduction
The number of articles about ‘‘vanadium’’ in the last decade
(2001–2010) doubled in comparison to the previous one
(1991–2000), from 1147 to 2351, from which 420 are about
‘‘vanadium’’ and proteins’’, after a research at PubMed.
Similarly, the number of papers selected with the word ‘‘actin’’
doubled in number, from 22 827 to 39 567, when these last two
decades are compared. However, studies about vanadium
interaction with actin are seldom. In fact, very few studies
concerning the interaction of vanadium with actin have been
so far described.1–3 One of these first studies demonstrated
that vanadate (vanadium(V)), upon binding to F-actin–ADP
subunits, increases the strength of actin–actin interactions,
stabilizing the F-actin filament,2 the polymerized form of
actin, for vanadate concentrations up to 2 mM, demonstrating
a similar behaviour to phosphate, whereas higher vanadate
concentrations destabilize F-actin.2 In a previous study, vanadate
was also compared with phosphate on its ability to induce
actin polymerization showing distinct effects.1 In another
study, it was analysed that vanadyl, vanadium(IV), interacts
with the monomeric actin, G-actin, revealing the presence of
one strong protein vanadium binding site, among others.3
More recently, it was demonstrated at our laboratory that
also vanadate oligomers, such as tetrameric (V4) and decameric
vanadate (decavanadate, V10), prevent G-actin polymerization,
more potently than monomeric vanadate.4 In fact, it was shown
that decavanadate, at concentrations as low as 68 mM, inhibits
50% of the extension of actin polymerization, whereas no effects
were observed for monomeric vanadate (V1) up to 2 mM.
4
Moreover, it was also verified that monomeric actin (G-actin)
stabilizes decavanadate species, by increasing its half-life time of
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decomposition, from 5 to 27 hours.4 Taken together, these results
reveal a new protein target for decavanadate and a specific
vanadium–protein interaction, confirmed later and described below.
Vanadium impact in biology, pharmacology and medicine is
well known, mainly after the discovery that the ‘‘muscle
inhibitor factor’’ present in ATP obtained from horse muscle
and responsible for Na+, K+-ATPase inhibition was, in fact,
vanadate.5 Vanadate acts as a transition state analogue for
phosphoenzyme hydrolysis, blocking the enzyme catalysis of
many enzymes, such as phosphatases and ATPases. In fact,
vanadate is known as a potent inhibitor of protein tyrosine
phosphatases (PTP), described as one of the main targets of
vanadate as an insulin enhancement agent, promoting the
increase of glucose uptake in several types of cells, among
other effects that prevent diabetes.6 Additionally, the usage of
vanadium as a tool to understand several biochemical processes
is also well recognized, since it shows many biological activities.2,7
Actin is one of the most abundant proteins in cells, being
involved in many cellular processes, such as cytoskeleton
structure and dynamics in non-muscle cells, andmuscle contraction
in muscular cells. Cellular studies have shown that vanadium
compounds induce changes in actin cytoskeleton, which are
responsible for morphological and cell proliferation alterations.8,9
These effects are probably induced through the inhibition of
protein tyrosine phosphatases, as referred above, or eventually
through reactive oxygen species generation, hence it is well
known that transition elements, such as vanadium, promote
Fenton-like reactions. These actions could explain, at least in part,
the increasing interest in vanadium for antitumor effects,10 as
well as antidiabetic agents, this latter process being induced
through an insulin dependent or insulin independent
pathway,6,11,12 although the mechanisms of action are still to
be clarified. It is believed that one of the main targets of
vanadium in the cell will be actin, regulating or preventing
many events.13,14 Therefore, it will be of extreme importance
to clarify the mode of interaction and the effects of vanadium
on actin structure and function. In the present report, a
combination of kinetic studies and 51V NMR, EPR, fluorescence
and UV/Vis spectroscopy techniques was used to establish the
interaction and/or effects of vanadyl, vanadate and decavanadate
on actin structure and function.
2. Decavanadate interaction with actin: cysteine
oxidation and vanadyl formation
As described above, it was revealed that decavanadate inter-
acts with actin. It was verified, by 51V NMR, that decavanadate
NMR signals broadened and decreased in intensity upon actin
titration (Fig. 1), whereas no significant changes were
observed for the other NMR vanadate oligomer signals.13
The broadening of V10 NMR signal, at physiological pH
and for a 0.5 mM V10 concentration (5 mM total vanadium
concentration), at 516 ppm (ascribed to decameric vanadate
species), increased 2-fold, from 139 to about 299 Hz, upon
titration with G-actin up to 100 mM (Fig. 1). Moreover, V10
signal decreases in intensity, with no changes observed in its
chemical shift in the presence of the protein. In contrast, no
effects were detected upon protein addition for the monomeric
vanadate NMR signal, at560 ppm, with a half-width of 69 Hz.
At the same experimental conditions, but in the presence of
0.2 mM ATP, the broadening effect was decreased from 2 to
1.4 (not shown), suggesting that ATP blocks decameric
vanadate interactions with actin. Conversely, the presence of
ATP induces the increase of the monomeric vanadate NMR
signal upon actin titration, at 560 ppm, from 70 to 83 Hz
(1.2 fold), without significant changes in the chemical shift.
Moreover, increasing the ionic strength, by 100 mM KCl
addition, the decavanadate broadening effect was also reduced
to 1.5-fold (not shown), indicating an electrostatic interaction
between the protein and decavanadate. Taken together, the
presence of ATP promotes the broadening of monomeric
NMR vanadate signal but it prevents the broadening of
decavanadate signals, suggesting that this nucleotide promotes
monomeric vanadate interaction with actin but on contrary
blocks decavanadate interaction.15 The broadening of
Fig. 1 Titration of decavanadate (5 mM total vanadate) with G-actin
in a medium containing 2 mM Tris (pH 7.5), 0.2 mM CaCl2; data are
plotted as means  SD and fitted with a Boltzmann sigmoidal
function. Broadening factor, F, represents the quotient between the
line width of the V10 signal, at 516 ppm, in the absence of actin and
upon protein addition. The results shown are the average of triplicate
experiments. In certain experimental conditions the error bar is within
the diameter of the symbol.
M. Aureliano
Dr Manuel Aureliano is an
Associate Professor of Bio-
chemistry at the Faculty of
Sciences and Technology,
University of Algarve, Faro,
Portugal. He obtained his
Biochemistry degree from
Coimbra University, Portugal,
where he also obtained his
MSc and PhD degrees,
working on decavanadate
interactions with muscle myosin
and sarcoplasmic reticulum
calcium pump, respectively. He
is regularly a peer reviewer (over
60) for numerous scientific jour-
nals (more than 20) and has served on the Editorial Boards of
scientific journals. To date, he has supervised and/or co-supervised
more than 80 post-doc, PhD, MSc and undergraduate students, and
has published about 60 peer-reviewed journal articles, reviews and
book chapters.
D
ow
nl
oa
de
d 
on
 3
0 
Ja
nu
ar
y 
20
12
Pu
bl
ish
ed
 o
n 
19
 O
ct
ob
er
 2
01
1 
on
 h
ttp
://
pu
bs
.rs
c.o
rg
 | d
oi:
10.
103
9/C
1M
T0
012
4H
View Online
18 Metallomics, 2012, 4, 16–22 This journal is c The Royal Society of Chemistry 2012
V10 NMR signals, upon protein titration, was previously
described for both myosin and Ca2+-ATPase, pointing out
specific decavanadate interactions with these three proteins
involved in the process of muscle contraction and its regulation.15,16
The broadening of monomeric vanadate, observed only in the
presence of ATP, was also previously described,15 suggesting
that ATP favours vanadate monomer interaction with the
protein, probably through formation of an ATP analogue
such as ATP.V or ADP.V.15,16 The broadening of NMR
vanadate signals upon interaction with proteins has also been
previously reported for several vanadate complexes.17–20
As observed by SDS-PAGE gel electrophoresis, the
isolation of actin, according to Pardee and Spudich,21 produced
a G-actin (42.3 kDa) with 99% purity (not shown), which allows
concluding that the NMR observations described above are due
to the interaction of the monomeric state of actin, G-actin, with
decavanadate. On the other hand, the addition of actin in its
polymerized form, F-actin, up to 50 mM, induces a much smaller
broadening of V10 signals (1.5-fold), in comparison with G-actin,
suggesting that decavanadate protein binding sites are encrusted
upon actin polymerization.22
Once it was observed that the decavanadate NMR signal is
affected upon actin interaction, it was asked: what will happen
to the protein structure and function in the presence of several
vanadium species, particularly with decavanadate? It is known
that actin contains five cysteines that could react with vanadate,
above all the so-called ‘‘fast cysteine’’ (Cys-374), more accessible
to the solvent. Therefore, cysteine oxidation was analysed by
UV/Vis spectroscopy, and the titration of actin cysteines was
performed with DTNB, as described previously13 using an
extinction coefficient at 412 nm of 10 900 M1 cm1 for the
colored product thionitrophenolate,13 after an exposure of
20 minutes to two different vanadate solutions, namely vanadate
(also called metavanadate and containing V1 species) and
decavanadate (containing V10 species). It was observed that only
V10 solution, but not vanadate, was able to oxidize F-actin Cys-
374 and additionally one of the core cysteine residues (not shown),
whereas for G-actin only the latter cysteine was affected (Fig. 2).
In fact, in contrast to F-actin, the ‘‘fast cysteine’’ from G-actin
remains in its reduced form, the oxidation of a core cysteine only
being observed (Fig. 2). WhenATP is present in the medium assay
all five cysteine residues are still in their reduced form upon
exposure to decavanadate for both G-actin and F-actin forms
of the protein (not shown). Apparently, as described above using
NMR spectroscopy, ATP protects the actin from the interaction
with decavanadate, also preventing cysteine oxidation.14 There-
fore, it was demonstrated that decavanadate interactions with
actin are of particular interest hence it was observed that only V10
species are able to promote protein cysteine oxidation.
Reaction of vanadate with protein thiol groups from
fructose-1,6-bisphosphate aldolase and from glyceraldehyde-
3-phosphate dehydrogenase, two enzymes involved in the
glycolysis process, was previously referred.23,24 Moreover, it
was also described that decavanadate is reduced by isocitrate
dehydrogenase,25 an enzyme involved in the citric acid cycle,
that is activated by adenosine nucleotide and calcium, but
inhibited by ATP. The oxidation of actin cysteines upon
decavanadate exposition leads to the question: does the oxidation
of actin cysteines imply decavanadate reduction to vanadyl?
In order to address this question, EPR studies were performed.
In fact, decavanadate interaction with both G- and F-actin
results in a concomitant vanadate reduction to vanadyl
(V(IV)).13,14 Typical EPR vanadium(IV) signals can be detected
upon decavanadate incubation with actin, whereas the
presence of ATP in the medium, once again, prevents
decavanadate reduction to vanadyl, as described above and
reported previously.13,14 But once vanadate is reduced to
vanadyl, does the reduced form of vanadium bind to actin?
In fact, as analysed by EPR spectroscopy, titration of
vanadyl with G-actin pointed out that vanadyl interacts with
G-actin. The extent of vanadyl binding to actin was measured
from themi =1/2 perpendicular line of the EPR spectra (not
shown) and the intensity of this line was plotted against
vanadyl concentration (Fig. 3). It was calculated that vanadyl
binds to actin with a Kd of 7.48  1.11 mM1 for G-actin and
43.05  5.34 mM1 for F-actin, with stoichiometry of approxi-
mately 1 and 4 vanadyl (VO2+) cations bound per G- or
F-actin molecule, respectively.13 Other studies performed with
ferritin described a stoichiometry of 16 vanadyl cations to one
protein molecule,26 this cation being recognized to bind to
several proteins, at the same and higher orders of magnitude
than the one described for actin.27–30 Similarly as it was
described above for decavanadate, the presence of ATP in
the assay medium prevents the interaction between vanadyl
and actin, hence no EPR signals are detected.13
Recently reviewed decavanadate insights into biological
systems have pointed out that this oligovanadate is either
more or less efficient than the corresponding simple oxovanadates
in targeting proteins, particularly at the nucleotide binding
site.7,31 According to data presented in this paper, it is
suggested that ATP prevents decavanadate interaction with
actin, hence it blocks cysteine oxidation and vanadyl formation,
among other effects described above. These observations
suggest that a decavanadate protein binding domain would
be eventually very close to or even at the nucleotide binding
site, such as it happens for several proteins such as calcium
Fig. 2 G-actin cysteine redox state, after 20 minutes exposition with
decavanadate. Titration of cysteines was performed with 0.1 mM
DTNB and 2 mM actin in 2 mM Tris (pH 7.5), and 0.2 mM CaCl2.
The increase in absorbance at 412 nm was continuously recorded over
10 min; to measure total cysteines the samples were treated afterwards
with 1% SDS, and the absorbance was measured, over 15–30 min,
until a steady value was reached. Titration with decavanadate
produced a dose-dependent decrease of G-actin total cysteines, while
Cys-374 remained in the reduced form. The results shown are the
average of triplicate experiments.
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ATPase, adenylate kinase, myosin and ABC ATPases
(ATP binding cassette ATPases), known to be inhibited by
decavanadate.7,31 However, several studies must be performed
to clarify the type and mode of decavanadate interaction with
actin. Apparently, decavanadate seems to interact differently
with the two forms of actin, the monomeric and the polymerized
form. Therefore, it will be extremely interesting to understand
the role of this oligovanadate ion in the several steps of the
process of actin polymerization.
3. Decavanadate and vanadyl effects on actin
structure and function
As described above, decavanadate revealed a very specific
interaction with actin by inducing vanadate reduction and
cysteine oxidation, with the concomitant binding of the
cationic species to both monomeric and polymerized forms
of actin. Previous studies referred to above described that
vanadate could increase the strength of actin–actin interactions
as phosphate does, but it could behave in a different mode to
phosphate, during the process of actin polymerization,
whereas vanadyl binds to actin.1–3 But do vanadate, vanadyl
and decavanadate species affect, to the same extent, the
process of actin polymerization and consequently many
processes that would occur in cells? To address this question
we analysed, by light scattering spectroscopy, the effects of all
three vanadium species on the extension of G-actin polymer-
ization into F-actin filaments (Fig. 4). Under exactly the same
experimental conditions, the three vanadium species affected
the actin polymerization in a very different way (Fig. 4).
Although for both vanadyl and decavanadate the inhibition
curve contains two behaviours, it was determined that the IC50
for the inhibition of polymerization reaction was lower for
decavanadate by comparison with vanadyl (68 and 300 mM,
respectively), whereas no effects were observed up to 2 mM
vanadate, as described previously for 8 mM G-actin in the
reaction medium.4,30 Therefore, for a decavanadate : actin
ratio of 8.5, decavanadate inhibits polymerization, whereas a
vanadyl : actin ratio of 37.5 is needed to induce the same effect.
In studies with other metals, it was described that a ratio of
9 for gadolinium:actin completely inhibited actin polymerization.32
Therefore, decavanadate is quite potent in preventing actin
polymerization.
It was also verified, at the same F-actin concentrations described
in the recent studies described above, that decavanadate and
vanadyl species do not induce depolymerisation of the actin
filaments to the same degree as they prevent actin polymerization.22
In fact, up to an 8 mM vanadium total concentration,
vanadate and decavanadate (meaning 0.8 mM V10) induce
F-actin depolymerisation by about 20% and 35%, respec-
tively, after two hours of incubation, whereas no effects were
detected for vanadyl up to 0.5 mM.22 Therefore, for the
vanadium concentration of up to 0.5 mM used in actin
polymerization studies no significant effects on F-actin
depolymerisation (less than 10%) were detected for all the
vanadium species.22
In order to further explore and compare the actin effects of
vanadate, vanadyl and decavanadate, fluorescence spectro-
scopy studies were performed to address specific vanadium
interactions with protein. It was verified that for vanadium
concentrations as low as 200 mM, vanadyl induces a total
quenching (100%) of G-actin intrinsic fluorescence, whereas
decavanadate increases its fluorescence up to 1.4 fold (Fig. 5).
Regarding F-actin, at the same experimental conditions, no
effects were detected on protein intrinsic fluorescence upon
titration with vanadyl (not shown). The lack of quenching of
F-actin intrinsic fluorescence by vanadyl suggests that the
tryptophans present in the protein are protected from vanadium
effects when the actin is present in its polymerized form.14,30
Eventually, actin conformational changes induced during
actin polymerization prevent the vanadium quenching. How-
ever, for higher vanadyl concentrations from 200 to 500 mM, a
maximum of 75% intrinsic protein quenching was observed, as
described elsewhere.30 On the other hand, a full quenching of
the intrinsic fluorescence of actin is observed for the mono-
meric state of the protein, G-actin, upon lower vanadyl
Fig. 3 Titration of both G-actin and F-actin with vanadyl. EPR
intensities from the transition peak mi = 1/2 perpendicular line, of
50 mM G-actin (K) or 30 mM F-actin (’) versus concentrations of
vanadyl sulfate. Medium containing 2 mM Tris (pH 7.5) and 0.2 mM
CaCl2. Data are plotted as means  SD. The results shown are the
average of triplicate experiments.
Fig. 4 Dependence of decavanadate (m), vanadyl (’) and vanadate
(K) concentrations on the extent of G-actin polymerization relative to
that in untreated G-actin (control) measured by the increase of light
scattering intensity, at lex = lem = 546 nm. G-actin (8 mM) was
incubated with the different vanadium species for 20 min, in a medium
containing 2 mM Tris–HCl (pH 7.5) and 0.2 mM CaCl2, before the
polymerization initiated by 100 mM KCl and 2 mM MgCl2, at 25 1C.
Data are plotted as means  SD. The results shown are the average of
triplicate experiments.
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concentrations (0.2 mM) (Fig. 5). Usually, described vanadate
protein quenching percentages are about 10 or 20%, such as
the ones verified for the quenching of myosin intrinsic fluores-
cence by decavanadate.14,33 The results obtained with vanadyl
(total quenching) point out that, apparently, in actin, its four
tryptophans are connected in a network in the tridimensional
structure of the protein. On the other hand, the different
residues contribute differently to the total fluorescence34 and
they may be differently affected by the metal. Moreover,
eventually, not all the several vanadyl binding sites contribute
equally to protein intrinsic quenching. It is believed that
further studies must be performed to clarify the vanadyl
interaction with actin.
Regarding protein intrinsic fluorescence, care must be taken
to evaluate the interaction of decavanadate or vanadate with
proteins, due to inner filter effects.14,30 However, many bio-
chemical studies using vanadium complexes and, particularly,
decavanadate (with absorptions at 360 and 400 nm7,31), do not
take into consideration those effects, which decreases the
fluorescence measurements accuracy. For the maximum dec-
avanadate concentration referred to in these studies, 20 mM,
(meaning 0.2 mM total vanadium), the absorbance values at
excitation and emission wavelengths used in assays (295 and
340 nm, respectively) attain to a sum of 0.841 O.D. (0.583 +
0.258), which is higher than the value obtained for monomeric
vanadate (0.475; 0.389 + 0.086) and for vanadyl (0.085;
0.064 + 0.021), for the same vanadium concentrations
(0.2 mM). Correction of the fluorescence intensities due to
these inner filter effects is desirable, and can be done using
proper equations, although its application is not clearly estab-
lished, or does not state what conditions would be clearly
appropriate,35 whereas some of them can be used even for
values of absorption up to 2.736 or as high as 5.37
Besides the effects on intrinsic fluorescence, it was also
observed that the actin hydrophobic surface, as determined
using the ANSA probe, increases upon decavanadate exposure
(2.6-fold), whereas vanadyl promotes its decrease by 15%,
suggesting that the changes caused by the former are clearly
different from the ones induced by vanadyl, favouring a
protein hydrophobic environment (Fig. 6), as described
recently.14,30 Therefore, decavanadate induced a less compact
protein intermediate state than the one induced by vanadyl,
wherein the hydrophobic interactions in the interior of the
protein decreased, leading to an increased exposure of hydro-
phobic surface relative to the native structure. However, both
decavanadate and vanadyl (up to 200 mM total vanadium)
increased the e-ATP exchange rate (k = 6.5  103 s1 and
4.47  103 s1, respectively, in comparison with the control:
k = 3.0  103 s1), and both species decreased ATP exchange
half-life time, denoting a more available cleft.14,30 Since it is
known that the larger the value of the ATP exchange rate, the
more available the cleft should be,38 it can be concluded that
vanadyl and decavanadate are clearly promoting structural
alterations on actin ATP binding sites.
Actin conformational changes upon vanadyl exposure were
also described by 1H NMR.30 Besides the effects described
with vanadyl, it was also observed, for the first time, and by
1H NMR, that decavanadate induced several protein confor-
mational changes (Fig. 7). G-actin exhibits a spectrum typical
of a well-folded protein (Fig. 7, bottom spectrum), with the
characteristic N-terminal acetyl group resonance at 2.05 ppm;
a second resonance can be observed upfield of this signal,
which has been assigned to the methyl groups of two methionines.
From the analysis of the 1H NMR spectra, one can infer that
100 mM decavanadate induces certain conformational changes
on G-actin, that are readily observable by both chemical shift
perturbations and decrease in the intensities of resonances
located in the methyl group and aliphatic regions (1–3 ppm),
as well as the aromatics and peptide-bond amide regions
(7–8 ppm) (Fig. 7, middle spectrum). Moreover, the addition
of 0.2 mM of ATP to the medium results in a change in the
actin structure, much less inferior than the one described
above (not shown).22 This effect of ATP on preventing the
conformational changes induced by decavanadate are in good
agreement with the results described above regarding cysteine
oxidation and vanadyl formation, among other effects, allowing
us to confirm without any doubt that ATP prevents the
interaction between the decameric vanadate species and actin.
Fig. 5 Titration of G-actin intrinsic fluorescence with vanadyl (m)
and decavanadate (’). G-actin (5 mM) was incubated for 20 minutes
with vanadium species, in 2 mM Tris–HCl (pH 7.5), 0.2 mM CaCl2.
The maximum of intrinsic fluorescence spectra (lex = 295 nm) was
plotted against vanadium concentrations, considering 1.00 the value
for native actin. The results shown are the average of, at least,
triplicate measurements.
Fig. 6 Determination of G-actin surface hydrophobicity by ANSA
binding. After treatment with different decavanadate (m) and vanadyl
(’) concentrations for 20 min, in 2 mM Tris–HCl (pH 7.5), 0.2 mM
CaCl2, the change in fluorescence intensity associated with the binding
of ANSA, to 9 mM actin surface hydrophobic regions, was measured
at 500 nm with lex = 370 nm. Data are plotted as means  SD. The
results shown are the average of triplicate experiments.
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The interactions of both vanadyl cation and vanadate anion
with actin may be a key to understand their in vivo and in vitro
effects in biology.39
As described above, the interaction of actin with decavanadate
increases the stability of the anion.4 In studies with decavanadate,
the half-life time should be always determined, normally
between 5 to 12 hours (25 1C) and 3 hours (37 1C), depending
on medium and temperature.7,31,40–43 Our studies were always
performed during a reaction time much less than the decavanadate
stability values, between 10 to 30 minutes, depending on the
studies, in order to assure that the biological effects were
mainly due to decavanadate.4,7,13,14,16,31 However, in the
majority of the vanadium studies, the stability of the vanadate
species or the vanadium complexes is not taken into account.
If we do not take into account the stability of the vanadium
species or complexes, we can only speculate about the
observed effects. It was recently described that other vanadium
species than the ones that are being studied can be observed
under the experimental conditions.20 In fact, even for vanadium
complexes, known to induce several insulin-like effects, it was
verified that other species can be formed, with vanadium
oxidation states other than the original one.20 Therefore,
besides the factors known to describe the vanadium complex
chemistry, namely, several oxidation states, similarity between
phosphate and vanadate, the occurrence of several vanadate
oligomers in solution and the formation of vanadium complexes
with many molecules of biological interest, we may add the
importance to address the stability of the vanadium complexes
or species and to certify the presence of decameric vanadate
species (responsible for the yellow colour of vanadate solutions),
before to attempt to attribute a certain biological activity or
effect to a vanadium complex or species.
4. Concluding remarks
A combination of 51V NMR, EPR, UV/Vis and fluorescence
spectroscopy techniques was used to determine the effects of
several vanadium species, namely vanadyl, vanadate and
decavanadate on G-actin and F-actin structure and function.
The studies reveal the presence of a vanadyl G-actin high
affinity binding sites, with a 1 : 1 actin : vanadium(IV) stoichiometry.
Also, a specific decavanadate interaction with actin was observed,
leading to cysteine oxidation and vanadyl formation. Both
decavanadate and vanadyl interactions with actin were prevented
by ATP. Putting it all together, it is proposed that the biological
effects of vanadium, whose major biological role is still to be
clarified, may be explained, at least in part, by its capacity to
interact with actin and to affect several biological processes where
actin may be involved. It is concluded in this paper that:
(i) decavanadate and vanadyl inhibit actin polymerization, at mM
concentrations; (ii) only decavanadate interaction with actin
induces cysteine oxidation and vanadyl formation, these effects
being prevented by ATP; (iii) decavanadate and vanadyl induce
actin conformational changes affecting the protein ATP binding
site; (iv) actin has high affinity binding sites for vanadyl. It is
suggested that actin, a protein involved in many cellular processes,
is a plausible protein target for decavanadate and, above all, for
vanadyl. By affecting actin structure and function vanadium can
regulate several cellular processes of great physiological signifi-
cance. It is believed that spontaneous interactions of both vanadyl
cation and vanadate anion with actin may be a key to understand
both in vivo and in vitro effects in biological processes involving
muscle and non-muscle actin.
In the present decade, we expect that important questions
will be answered, for instance: (i) will we be able to characterize
the first X-ray structures of vanadyl–actin and decavanadate–
actin complexes? (ii) Will we understand the role of vanadyl,
decavanadate and vanadate in the several steps of the process
of actin polymerization/depolymerisation? (iii) Will we be able
to understand the contribution of vanadium interaction with
actin to the effects of vanadium as insulin enhancement and as
anticancer agents, among other effects? These questions and
others will require continuous development of new approaches
to explore the vanadium effects in these complex systems.
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DTNB 5,50-dithio-bis(2-nitrobenzoic acid)
G-actin monomeric actin
F-actin filamentous polymerized actin
Acknowledgements
This work was supported by CCMAR funding. S. Ramos
would like to thank the Portuguese ‘‘Fundac¸a˜o para a Cieˆncia
e Tecnologia’’ (FCT) for the PhD grant SFRH/BD/29712/
2006.
References
1 S. C. El-Saleh and P. Johnson, Int. J. Biol. Macromol., 1982, 4, 430.
2 C. Combeau and M.-F. Carlier, J. Biol. Chem., 1988, 263, 17429.
Fig. 7 1H NMR spectra of 63 mMG-actin (bottom line) plus 0.1 mM
decavanadate (middle line) in the absence (A) and in the presence of
0.2 mM ATP (B). The top spectra are the difference spectra. The
spectra were obtained in the medium containing 2 mMTris–HCl (pH 7.5),
0.2 mM CaCl2. All spectra were acquired at a temperature of 298 K
using a Bruker Avance III 600 MHz spectrometer equipped with a
TCI-Z cryoprobe and a temperature control unit. 256 free-induction
decays were accumulated per spectrum, with an inter-scan delay of 1.5 s.
D
ow
nl
oa
de
d 
on
 3
0 
Ja
nu
ar
y 
20
12
Pu
bl
ish
ed
 o
n 
19
 O
ct
ob
er
 2
01
1 
on
 h
ttp
://
pu
bs
.rs
c.o
rg
 | d
oi:
10.
103
9/C
1M
T0
012
4H
View Online
22 Metallomics, 2012, 4, 16–22 This journal is c The Royal Society of Chemistry 2012
3 F. An, B. Y. Zhang, B. W. Chen and K. Wang, Chem. J. Chin.
Univ., 1996, 17, 667.
4 S. Ramos, M. Manuel, T. Tiago, R. O. Duarte, J. Martins,
C. Gutie´rrez-Merino, J. J. G. Moura and M. Aureliano, J. Inorg.
Biochem., 2006, 100, 1734.
5 L. C. Cantley Jr., L. Josephson, R. Warner, M. Yanagisawa,
C. Lechene and G. Guidotti, J. Biol. Chem., 1977, 252, 7421.
6 E. Tsiani, E. Bogdanovic, A. Sorisky, L. Nagy and I. G. Fantus,
Diabetes, 1998, 47, 1676.
7 M. Aureliano and D. C. Crans, J. Inorg. Biochem., 2009, 103, 536.
8 X.-G. Yang, X.-D. Yang, L. Yuan, K. Wang and D. C. Crans,
Pharm. Res., 2004, 21, 1026.
9 J. Rivadeneira, D. A. Barrio, G. Arrambide, D. Gambino,
L. Bruzzone and S. B. Etcheverry, J. Inorg. Biochem., 2009,
103, 633.
10 A. M. Evangelou, Crit. Rev. Oncol. Hematol., 2002, 42, 249.
11 F. Yraola, S. Garcia-Vicente, L. Marti, F. Albericio, A. Zorzano
and M. Royo, Chem. Biol. Drug Des., 2007, 69, 423.
12 J. Li, G. Elberg, N. Sekar, Z. B. He and Y. Shechter, Endocrinology,
1997, 138, 2274.
13 S. Ramos, R. O. Duarte, J. J. G. Moura and M. Aureliano, Dalton
Trans., 2009, 7985.
14 S. Ramos, J. J. G. Moura and M. Aureliano, J. Inorg. Biochem.,
2010, 104, 1234.
15 M. Aureliano and V. M. C. Madeira, Biochim. Biophys. Acta, Mol.
Cell Res., 1994, 1221, 259.
16 T. Tiago, M. Aureliano and C. Gutierrez-Merino, Biochemistry,
2004, 43, 5551.
17 A. Butler, M. J. Danzitz and H. J. Eckert, J. Am. Chem. Soc., 1987,
109, 1864.
18 P. J. Stankiewicz, M. J. Gresser, A. S. Tracey and L. F. Hass,
Biochemistry, 1987, 26, 1264.
19 L. Wittenkeller, W. Lin, C. Diven, A. Ciaccia, F. Wang and
D. Mota de Freitas, Inorg. Chem., 2001, 40, 1654.
20 M. Aureliano, F. Henao, T. Tiago, R. O. Duarte, J. J. G. Moura,
B. Baruah and D. C. Crans, Inorg. Chem., 2008, 47, 5677.
21 J. D. Pardee and J. A. Spudich, Methods Enzymol., 1982, 85, 164.
22 S. Ramos, PhD Thesis, New University of Lisbon, 2011.
23 I. Dalle-Donne, R. Rossi, D. Giustarini, N. Gagliano, L. Lusini,
A. Milzani, P. Di Simplicio and R. Colombo, Free Radical Biol.
Med., 2001, 31, 1075.
24 D. C. Crans, K. Sudhakar and T. J. Zamborelli, Biochemistry,
1992, 31, 6812.
25 J. E. Benabe, L. A. Echegoyen, B. Pastrana and M. Martınez-
Maldonado, J. Biol. Chem., 1987, 262, 9555.
26 N. D. Chasteen and E. C. Theil, J. Biol. Chem., 1982, 257, 7672.
27 N. D. Chasteen, in Structure and Bonding, ed. M. J. Clarke,
J. B. Goodenough, J. A. Ibers, C. K. Jørgensen, D. M. P. Mingos,
J. B. Neilands, G. A. Palmer, D. Reinen, P. J. Sadler, R. Weiss and
R. J. P. Williams, Springer-Verlag, New York, 1983, pp. 105–138.
28 L. WanHua, L. HuiXue, Z. LiJun, Y. XiaoDa and K. Wang, Chin.
Sci. Bull., 2007, 52, 2775.
29 E. G. Ferrer, A. Bosch, O. Yantorno and E. J. Baran, Bioorg. Med.
Chem., 2008, 16, 3878.
30 S. Ramos, R. M. Almeida, J. J. G. Moura and M. Aureliano,
J. Inorg. Biochem., 2011, 105, 777.
31 M. Aureliano, Dalton Trans., 2009, 9093.
32 C. G. dos Reme´dios and J. A. Barden, Biochem. Biophys. Res.
Commun., 1977, 77, 1339.
33 T. Tiago, M. Aureliano and C. Gutie´rrez-Merino, J. Fluoresc.,
2002, 12, 87.
34 K. K. Turoverov and I. M. Kuznetsova, J. Fluoresc., 2003, 13, 41.
35 J. R. Lackowicz, Principles of Fluorescence Spectroscopy, Plenum
Press, New York, 1983, p. 56.
36 M. Kubista, R. Sloback, S. Eriksson and B. Albinsson, Analyst,
1994, 119, 417.
37 B. Birdsall, R. W. King, M. R. Wheeler, C. A. Lewis Jr,
S. R. Goode, R. B. Dunlap and G. C. Roberts, Anal. Biochem.,
1983, 132, 353.
38 I. Dalle-Donne, R. Rossi, D. Giustarini, N. Gagliano, P. Di
Simplicio, R. Colombo and A. Milzani, Free Radical Biol. Med.,
2002, 32, 927.
39 D. C. Crans, R. L. Bunch and L. A. Theisen, J. Am. Chem. Soc.,
1989, 111, 7597.
40 M. Aureliano, N. Joaquim, A. Sousa, H. Martins and
J. M. Coucelo, J. Inorg. Biochem., 2002, 90, 159.
41 R. Gaˆndara, S. S. Soares, H. Martins and M. Aureliano, J. Inorg.
Biochem., 2005, 99, 2355.
42 S. S. Soares, H. Martins, R. O. Duarte, J. J. G. Moura, J. Coucelo,
C. Gutie´rrez-Merino andM.Aureliano, J. Inorg. Biochem., 2007, 101, 80.
43 S. S. Soares, C. Gutie´rrez-Merino and M. Aureliano, Aquat.
Toxicol., 2007, 83, 1.
D
ow
nl
oa
de
d 
on
 3
0 
Ja
nu
ar
y 
20
12
Pu
bl
ish
ed
 o
n 
19
 O
ct
ob
er
 2
01
1 
on
 h
ttp
://
pu
bs
.rs
c.o
rg
 | d
oi:
10.
103
9/C
1M
T0
012
4H
View Online
